Nova Patents
EP0396232A2

Oral rinse compositions.

Abstract

Mouthrinses containing sanguinarine of superior efficacy and increased uptake into dental plaque are attained by the development of stable mouthrinses adjusted to a pH in the range of 4.0 to 5.6, preferably about 4.5. Compositions may contain a zinc salt as an optional ingredient. Various types of buffer systems are described.

Term

Term ended

Projected expiry passed 12 March 2010, 16.5 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

12 claims: 8 independent, 4 dependent

  1. 1
    An oral composition containing benzophenan­thridine alkaloid characterized in that it is stabilized by the presence of an orally acceptable buffer system buffered to acid pH.
  2. 3
    A stable oral rinse composition comprising from about 0.01 to 0.2% by weight of benzophenan­thridine alkaloid in an aqueous solution and a buffer system in a quantity sufficient to adjust the pH of said composition to a pH in the range of 4.0 to 5.6.
  3. 5
    A composition as claimed in any one of Claims 1 to 4 characterized in that it comprises a water-­soluble zinc salt.
  4. 7
    A composition as claimed in any one of Claims 1 to 6 characterized in that the said buffer system is selected from the group consisting of (a) sodium citrate and citric acid, (b) sodium acetate and acetic acid, and (c) sodium tartrate and tartaric acid.
  5. 8
    A composition as claimed in any one of Claims 1 to 7 characterized in that it further comprises 5 to 25% by weight ethyl alcohol, 2 to 15% by weight of humectant, 0.1 to 3% by weight surface active agent, 0.02 to 1% by weight sweetening agent, and 0.05 to 0.4% by weight flavoring agent.
  6. 10
    A composition as claimed in any one of Claims 1 to 9 characterized in that it has a pH of about 4.5.
  7. 11
    A composition as claimed in any one of Claims 1 to 10 characterized in that the said alkaloid is selected from the group consisting of water soluble salts of sanguinarine, chelerythrine, sanguilutine, chelilutine, chelirubine, and sanguirubine;and in that the said buffer system is selected from (a) sodium citrate and citric acid, (b) sodium acetate and acetic acid, and (c) sodium tartrate and tartaric acid.
  8. 12
    A composition as claimed in any one of the preceding claims in which any surface active agent present if a nonionic block copolymer of polyoxy­ethylene and polyoxypropylene has an unsaturation of less than 45 meq/mg.